Tofacitinib in ulcerative colitis

被引：13

作者：

Archer, Thomas P. ^{[1
,2
]}

Moran, Gordon W. ^{[1
,2
]}

Ghosh, Subrata ^{[3
]}

机构：

[1] Nottingham Univ Hosp NHS Trust, NIHR Biomed Res Unit Gastrointestinal & Liver Dis, Nottingham, England

[2] Univ Nottingham, Nottingham NG7 2RD, England

[3] Univ Calgary, Inflammatory Bowel Dis Clin, TRW Bldg,3280 Hosp DR NW, Calgary, AB T2N 4N1, Canada

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 05期

关键词：

CP-690,550 (tofacitinib); inflammatory bowel disease; JAK inhibitor; ulcerative colitis; ACTIVE RHEUMATOID-ARTHRITIS; JANUS KINASE INHIBITOR; SELECTIVE JAK1 INHIBITOR; MAINTENANCE THERAPY; INADEQUATE RESPONSE; FILGOTINIB GLPG0634; DOUBLE-BLIND; CP-690,550; PLACEBO; INFLAMMATION;

D O I：

10.2217/imt-2015-0031

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Cytokines orchestrate immune and inflammatory responses involved in the pathogenesis of ulcerative colitis (UC). Protein kinases are essential for signal transduction in eukaryotic cells. Janus kinases (JAKs) are a family of protein tyrosine kinases that play a pivotal role in cytokine receptor signaling. Indeed, a major subgroup of cytokines use Type I and II cytokine receptors which signal via the activation of JAKs. Tofacitinib is an oral JAK inhibitor that has been studied in autoimmune pathologies, including UC and rheumatoid arthritis with good overall efficacy and acceptable safety profile. This literature review was performed with the goal of summarizing the knowledge on JAK inhibitors in UC treatment.

引用

页码：495 / 502

页数：8

共 60 条

[1]

The Current STATus of lymphocyte signaling: new roles for old players [J].

Adamson, Adewole S. ;

Collins, Kalonji ;

Laurence, Arian ;

O'Shea, John J. .

CURRENT OPINION IN IMMUNOLOGY, 2009, 21 (02) :161-166

[2]

Investigation of Crohn's Disease Risk Loci in Ulcerative Colitis Further Defines Their Molecular Relationship [J].

Anderson, Carl A. ;

Massey, Dunecan C. O. ;

Barrett, Jeffrey C. ;

Prescott, Natalie J. ;

Tremelling, Mark ;

Fisher, Sheila A. ;

Gwilliam, Rhian ;

Jacob, Jemima ;

Nimmo, Elaine R. ;

Drummond, Hazel ;

Lees, Charlie W. ;

Onnie, Clive M. ;

Hanson, Catherine ;

Blaszczyk, Katarzyna ;

Ravindrarajah, Radhi ;

Hunt, Sarah ;

Varma, Dhiraj ;

Hammond, Naomi ;

Lewis, Gregory ;

Attlesey, Heather ;

Watkins, Nick ;

Ouwehand, Willem ;

Strachan, David ;

McArdle, Wendy ;

Lewis, Cathryn M. ;

Lobo, Alan ;

Sanderson, Jeremy ;

Jewell, Derek P. ;

Deloukas, Panos ;

Mansfield, John C. ;

Mathew, Christopher G. ;

Satsangi, Jack ;

Parkes, Miles .

GASTROENTEROLOGY, 2009, 136 (02) :523-529

[3]

Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity [J].

Babon, Jeffrey J. ;

Kershaw, Nadia J. ;

Murphy, James M. ;

Varghese, Leila N. ;

Laktyushin, Artem ;

Young, Samuel N. ;

Lucet, Isabelle S. ;

Norton, Raymond S. ;

Nicola, Nicos A. .

IMMUNITY, 2012, 36 (02) :239-250

[4]

Molecular phylogeny within type I cytokines and their cognate receptors [J].

Boulay, JL ;

O'Shea, JJ ;

Paul, WE .

IMMUNITY, 2003, 19 (02) :159-163

[5]

Burmester Rb, 2011, ARTHRITIS RHEUM, V63, P718

[6]

JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice [J].

Chang, Betty Y. ;

Zhao, Feifei ;

He, Xiaodong ;

Ren, Hong ;

Braselmann, Sylvia ;

Taylor, Vanessa ;

Wicks, Joan ;

Payan, Donald G. ;

Grossbard, Elliott B. ;

Pine, Polly R. ;

Bullar, Daniel C. .

JOURNAL OF IMMUNOLOGY, 2009, 183 (03) :2183-2192

[7]

JAK3: A two-faced player in hematological disorders [J].

Cornejo, Melanie G. ;

Boggon, Titus J. ;

Mercher, Thomas .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (12) :2376-2379

[8]

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis [J].

Feagan, Brian G. ;

Rutgeerts, Paul ;

Sands, Bruce E. ;

Hanauer, Stephen ;

Colombel, Jean-Frederic ;

Sandborn, William J. ;

Van Assche, Gert ;

Axler, Jeffrey ;

Kim, Hyo-Jong ;

Danese, Silvio ;

Fox, Irving ;

Milch, Catherine ;

Sankoh, Serap ;

Wyant, Tim ;

Xu, Jing ;

Parikh, Asit .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :699-710

[9]

Fleischmann R, 2011, ANN RHEUM DIS S3, V70, P170

[10]

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis [J].

Fleischmann, Roy ;

Kremer, Joel ;

Cush, John ;

Schulze-Koops, Hendrik ;

Connell, Carol A. ;

Bradley, John D. ;

Gruben, David ;

Wallenstein, Gene V. ;

Zwillich, Samuel H. ;

Kanik, Keith S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06) :495-507

← 1 2 3 4 5 6 →